Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy
Identifieur interne : 001A84 ( Istex/Corpus ); précédent : 001A83; suivant : 001A85Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy
Auteurs : Alexei Korchounov ; Gregory BogomazovSource :
- Movement Disorders [ 0885-3185 ] ; 2006-12.
English descriptors
- KwdEn :
Abstract
The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full‐time–employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self‐perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full‐time–employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2‐year randomized double‐blind placebo‐controlled study of ENT adjunctive therapy. The outcome measures were the number of full‐time–employed patients at study end, cumulative days of medical absenteeism, patient‐completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale–based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self‐perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21123
Links to Exploration step
ISTEX:C100D1EB96F2628E5CB83422D95BDD30C8E3D788Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy</title><author><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name><affiliation><mods:affiliation>Parkinson Clinic, Bad Nauheim, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Hospital of Misr International University, Cairo, Egypt</mods:affiliation></affiliation></author><author><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name><affiliation><mods:affiliation>Center for Investigation of Movement Disorders, Moscow, Russia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C100D1EB96F2628E5CB83422D95BDD30C8E3D788</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.21123</idno><idno type="url">https://api.istex.fr/document/C100D1EB96F2628E5CB83422D95BDD30C8E3D788/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001A84</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy</title><author><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name><affiliation><mods:affiliation>Parkinson Clinic, Bad Nauheim, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Hospital of Misr International University, Cairo, Egypt</mods:affiliation></affiliation></author><author><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name><affiliation><mods:affiliation>Center for Investigation of Movement Disorders, Moscow, Russia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-12">2006-12</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2220">2220</biblScope><biblScope unit="page" to="2224">2224</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C100D1EB96F2628E5CB83422D95BDD30C8E3D788</idno><idno type="DOI">10.1002/mds.21123</idno><idno type="ArticleID">MDS21123</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dyskinesia</term><term>employment</term><term>entacapone</term><term>retirement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full‐time–employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self‐perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full‐time–employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2‐year randomized double‐blind placebo‐controlled study of ENT adjunctive therapy. The outcome measures were the number of full‐time–employed patients at study end, cumulative days of medical absenteeism, patient‐completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale–based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self‐perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability. © 2006 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Alexei Korchounov MD</name><affiliations><json:string>Parkinson Clinic, Bad Nauheim, Germany</json:string><json:string>Hospital of Misr International University, Cairo, Egypt</json:string></affiliations></json:item><json:item><name>Gregory Bogomazov MD</name><affiliations><json:string>Center for Investigation of Movement Disorders, Moscow, Russia</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>entacapone</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>retirement</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>employment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dyskinesia</value></json:item></subject><language><json:string>eng</json:string></language><abstract>The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full‐time–employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self‐perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full‐time–employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2‐year randomized double‐blind placebo‐controlled study of ENT adjunctive therapy. The outcome measures were the number of full‐time–employed patients at study end, cumulative days of medical absenteeism, patient‐completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale–based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P > 0.0001), improved self‐perception of disability progression over 2 years (change score 1.0 vs. 4.5; P > 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability. © 2006 Movement Disorder Society</abstract><qualityIndicators><score>5.774</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1517</abstractCharCount><pdfWordCount>3182</pdfWordCount><pdfCharCount>19843</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>216</abstractWordCount></qualityIndicators><title>Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy</title><genre><json:string>Serial article</json:string></genre><host><volume>21</volume><pages><total>5</total><last>2224</last><first>2220</first></pages><issn><json:string>0885-3185</json:string></issn><issue>12</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1002/mds.21123</json:string></doi><id>C100D1EB96F2628E5CB83422D95BDD30C8E3D788</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/C100D1EB96F2628E5CB83422D95BDD30C8E3D788/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/C100D1EB96F2628E5CB83422D95BDD30C8E3D788/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/C100D1EB96F2628E5CB83422D95BDD30C8E3D788/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2006</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy</title><author><persName><forename type="first">Alexei</forename><surname>Korchounov</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Parkinson Clinic Bad Nauheim, Franz‐Groedel‐Strasse 6, 61231 Bad Nauheim, Germany</p></note><affiliation>Parkinson Clinic, Bad Nauheim, Germany</affiliation><affiliation>Hospital of Misr International University, Cairo, Egypt</affiliation></author><author><persName><forename type="first">Gregory</forename><surname>Bogomazov</surname><roleName type="degree">MD</roleName></persName><affiliation>Center for Investigation of Movement Disorders, Moscow, Russia</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-12"></date><biblScope unit="vol">21</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2220">2220</biblScope><biblScope unit="page" to="2224">2224</biblScope></imprint></monogr><idno type="istex">C100D1EB96F2628E5CB83422D95BDD30C8E3D788</idno><idno type="DOI">10.1002/mds.21123</idno><idno type="ArticleID">MDS21123</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full‐time–employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self‐perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full‐time–employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2‐year randomized double‐blind placebo‐controlled study of ENT adjunctive therapy. The outcome measures were the number of full‐time–employed patients at study end, cumulative days of medical absenteeism, patient‐completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale–based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self‐perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability. © 2006 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>entacapone</term></item><item><term>retirement</term></item><item><term>employment</term></item><item><term>dyskinesia</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-03-17">Received</change><change when="2006-06-15">Registration</change><change when="2006-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/C100D1EB96F2628E5CB83422D95BDD30C8E3D788/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v21:12</doi><numberingGroup><numbering type="journalVolume" number="21">21</numbering><numbering type="journalIssue">12</numbering></numberingGroup><coverDate startDate="2006-12">December 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="350" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21123</doi><idGroup><id type="unit" value="MDS21123"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2006-03-17"></event><event type="manuscriptRevised" date="2006-06-12"></event><event type="manuscriptAccepted" date="2006-06-15"></event><event type="publishedOnlineEarlyUnpaginated" date="2006-10-16"></event><event type="firstOnline" date="2006-10-16"></event><event type="publishedOnlineFinalForm" date="2006-12-19"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2220</numbering><numbering type="pageLast">2224</numbering></numberingGroup><correspondenceTo>Parkinson Clinic Bad Nauheim, Franz‐Groedel‐Strasse 6, 61231 Bad Nauheim, Germany</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21123.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="16"></count><count type="wordTotal" number="3217"></count></countGroup><titleGroup><title type="main" xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy</title><title type="short" xml:lang="en">ENT + LD and Retirement in PD Patients</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Alexei</givenNames><familyName>Korchounov</familyName><degrees>MD</degrees></personName><contactDetails><email>a.korchounov@parkinsonzentrum.de</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Gregory</givenNames><familyName>Bogomazov</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="DE" type="organization"><unparsedAffiliation>Parkinson Clinic, Bad Nauheim, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="EG" type="organization"><unparsedAffiliation>Hospital of Misr International University, Cairo, Egypt</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="RU" type="organization"><unparsedAffiliation>Center for Investigation of Movement Disorders, Moscow, Russia</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">entacapone</keyword><keyword xml:id="kwd3">retirement</keyword><keyword xml:id="kwd4">employment</keyword><keyword xml:id="kwd5">dyskinesia</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full‐time–employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self‐perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full‐time–employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2‐year randomized double‐blind placebo‐controlled study of ENT adjunctive therapy. The outcome measures were the number of full‐time–employed patients at study end, cumulative days of medical absenteeism, patient‐completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale–based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; <i>P</i> = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; <i>P</i> < 0.0001), improved self‐perception of disability progression over 2 years (change score 1.0 vs. 4.5; <i>P</i> < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability. © 2006 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>ENT + LD and Retirement in PD Patients</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy</title></titleInfo><name type="personal"><namePart type="given">Alexei</namePart><namePart type="family">Korchounov</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Clinic, Bad Nauheim, Germany</affiliation><affiliation>Hospital of Misr International University, Cairo, Egypt</affiliation><description>Correspondence: Parkinson Clinic Bad Nauheim, Franz‐Groedel‐Strasse 6, 61231 Bad Nauheim, Germany</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gregory</namePart><namePart type="family">Bogomazov</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Center for Investigation of Movement Disorders, Moscow, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2006-12</dateIssued><dateCaptured encoding="w3cdtf">2006-03-17</dateCaptured><dateValid encoding="w3cdtf">2006-06-15</dateValid><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">16</extent><extent unit="words">3217</extent></physicalDescription><abstract lang="en">The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full‐time–employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self‐perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full‐time–employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2‐year randomized double‐blind placebo‐controlled study of ENT adjunctive therapy. The outcome measures were the number of full‐time–employed patients at study end, cumulative days of medical absenteeism, patient‐completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale–based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self‐perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability. © 2006 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>entacapone</topic><topic>retirement</topic><topic>employment</topic><topic>dyskinesia</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>2220</start><end>2224</end><total>5</total></extent></part></relatedItem><identifier type="istex">C100D1EB96F2628E5CB83422D95BDD30C8E3D788</identifier><identifier type="DOI">10.1002/mds.21123</identifier><identifier type="ArticleID">MDS21123</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A84 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001A84 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:C100D1EB96F2628E5CB83422D95BDD30C8E3D788
|texte= Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy
}}
| This area was generated with Dilib version V0.6.23. |  |